Victor Garcia1, Ankit Gilani1, Brian Shkolnik1, Varunkumar Pandey1, Frank Fan Zhang1, Rambabu Dakarapu1, Shyam K Gandham1, N Rami Reddy1, Joan P Graves1, Artiom Gruzdev1, Darryl C Zeldin1, Jorge H Capdevila1, John R Falck1, Michal Laniado Schwartzman2. 1. From the Department of Pharmacology, New York Medical College School of Medicine, Valhalla (V.G., A.G., B.S., V.P., F.F.Z., M.L.S.); Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas (R.D., S.K.G., N.R.R., J.R.F.); Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC (J.P.G., A.G., D.C.Z.); and Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.H.C.). 2. From the Department of Pharmacology, New York Medical College School of Medicine, Valhalla (V.G., A.G., B.S., V.P., F.F.Z., M.L.S.); Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas (R.D., S.K.G., N.R.R., J.R.F.); Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC (J.P.G., A.G., D.C.Z.); and Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.H.C.). Michal_schwartzman@nymc.edu.
Abstract
RATIONALE: 20-Hydroxyeicosatetraenoic acid (20-HETE), one of the principle cytochrome P450 eicosanoids, is a potent vasoactive lipid whose vascular effects include stimulation of smooth muscle contractility, migration, and proliferation, as well as endothelial cell dysfunction and inflammation. Increased levels of 20-HETE in experimental animals and in humans are associated with hypertension, stroke, myocardial infarction, and vascular diseases. OBJECTIVE: To date, a receptor/binding site for 20-HETE has been implicated based on the use of specific agonists and antagonists. The present study was undertaken to identify a receptor to which 20-HETE binds and through which it activates a signaling cascade that culminates in many of the functional outcomes attributed to 20-HETE in vitro and in vivo. METHODS AND RESULTS: Using crosslinking analogs, click chemistry, binding assays, and functional assays, we identified G-protein receptor 75 (GPR75), currently an orphan G-protein-coupled receptor (GPCR), as a specific target of 20-HETE. In cultured human endothelial cells, 20-HETE binding to GPR75 stimulated Gαq/11 protein dissociation and increased inositol phosphate accumulation and GPCR-kinase interacting protein-1-GPR75 binding, which further facilitated the c-Src-mediated transactivation of epidermal growth factor receptor. This results in downstream signaling pathways that induce angiotensin-converting enzyme expression and endothelial dysfunction. Knockdown of GPR75 or GPCR-kinase interacting protein-1 prevented 20-HETE-mediated endothelial growth factor receptor phosphorylation and angiotensin-converting enzyme induction. In vascular smooth muscle cells, GPR75-20-HETE pairing is associated with Gαq/11- and GPCR-kinase interacting protein-1-mediated protein kinase C-stimulated phosphorylation of MaxiKβ, linking GPR75 activation to 20-HETE-mediated vasoconstriction. GPR75 knockdown in a mouse model of 20-HETE-dependent hypertension prevented blood pressure elevation and 20-HETE-mediated increases in angiotensin-converting enzyme expression, endothelial dysfunction, smooth muscle contractility, and vascular remodeling. CONCLUSIONS: This is the first report to identify a GPCR target for an eicosanoid of this class. The discovery of 20-HETE-GPR75 pairing presented here provides the molecular basis for the signaling and pathophysiological functions mediated by 20-HETE in hypertension and cardiovascular diseases.
RATIONALE: 20-Hydroxyeicosatetraenoic acid (20-HETE), one of the principle cytochrome P450eicosanoids, is a potent vasoactive lipid whose vascular effects include stimulation of smooth muscle contractility, migration, and proliferation, as well as endothelial cell dysfunction and inflammation. Increased levels of 20-HETE in experimental animals and in humans are associated with hypertension, stroke, myocardial infarction, and vascular diseases. OBJECTIVE: To date, a receptor/binding site for 20-HETE has been implicated based on the use of specific agonists and antagonists. The present study was undertaken to identify a receptor to which 20-HETE binds and through which it activates a signaling cascade that culminates in many of the functional outcomes attributed to 20-HETE in vitro and in vivo. METHODS AND RESULTS: Using crosslinking analogs, click chemistry, binding assays, and functional assays, we identified G-protein receptor 75 (GPR75), currently an orphan G-protein-coupled receptor (GPCR), as a specific target of 20-HETE. In cultured human endothelial cells, 20-HETE binding to GPR75 stimulated Gαq/11 protein dissociation and increased inositol phosphate accumulation and GPCR-kinase interacting protein-1-GPR75 binding, which further facilitated the c-Src-mediated transactivation of epidermal growth factor receptor. This results in downstream signaling pathways that induce angiotensin-converting enzyme expression and endothelial dysfunction. Knockdown of GPR75 or GPCR-kinase interacting protein-1 prevented 20-HETE-mediated endothelial growth factor receptor phosphorylation and angiotensin-converting enzyme induction. In vascular smooth muscle cells, GPR75-20-HETE pairing is associated with Gαq/11- and GPCR-kinase interacting protein-1-mediated protein kinase C-stimulated phosphorylation of MaxiKβ, linking GPR75 activation to 20-HETE-mediated vasoconstriction. GPR75 knockdown in a mouse model of 20-HETE-dependent hypertension prevented blood pressure elevation and 20-HETE-mediated increases in angiotensin-converting enzyme expression, endothelial dysfunction, smooth muscle contractility, and vascular remodeling. CONCLUSIONS: This is the first report to identify a GPCR target for an eicosanoid of this class. The discovery of 20-HETE-GPR75 pairing presented here provides the molecular basis for the signaling and pathophysiological functions mediated by 20-HETE in hypertension and cardiovascular diseases.
Authors: Cheng-Chia Wu; Jennifer Cheng; Frank Fan Zhang; Katherine H Gotlinger; Mukul Kelkar; Yilun Zhang; Jawahar L Jat; John R Falck; Michal L Schwartzman Journal: Hypertension Date: 2011-02-14 Impact factor: 10.190
Authors: Jennifer Cheng; Cheng-Chia Wu; Katherine H Gotlinger; Frank Zhang; John R Falck; Dubasi Narsimhaswamy; Michal Laniado Schwartzman Journal: J Pharmacol Exp Ther Date: 2009-10-19 Impact factor: 4.030
Authors: Cheng-Chia Wu; Shaojun Mei; Jennifer Cheng; Yan Ding; Adam Weidenhammer; Victor Garcia; Fan Zhang; Katherine Gotlinger; Vijaya L Manthati; John R Falck; Jorge H Capdevila; Michal L Schwartzman Journal: J Am Soc Nephrol Date: 2013-05-02 Impact factor: 10.121
Authors: Craig Southern; Jennifer M Cook; Zaynab Neetoo-Isseljee; Debra L Taylor; Catherine A Kettleborough; Andy Merritt; Daniel L Bassoni; William J Raab; Elizabeth Quinn; Tom S Wehrman; Anthony P Davenport; Andrew J Brown; Andrew Green; Mark J Wigglesworth; Steve Rees Journal: J Biomol Screen Date: 2013-02-08
Authors: Bo Liu; Zoheb Hassan; Stefan Amisten; Aileen J King; James E Bowe; Guo Cai Huang; Peter M Jones; Shanta J Persaud Journal: Diabetologia Date: 2013-08-27 Impact factor: 10.122
Authors: Stephen J Peterson; Joseph I Shapiro; Ellen Thompson; Shailendra Singh; Lu Liu; Jeremy A Weingarten; Kathleen O'Hanlon; Angelica Bialczak; Siddharth R Bhesania; Nader G Abraham Journal: Obesity (Silver Spring) Date: 2019-01 Impact factor: 5.002
Authors: Varunkumar Pandey; Victor Garcia; Ankit Gilani; Priyanka Mishra; Frank Fan Zhang; Mahesh P Paudyal; John R Falck; Alberto Nasjletti; Wen-Hui Wang; Michal Laniado Schwartzman Journal: J Pharmacol Exp Ther Date: 2017-09-14 Impact factor: 4.030
Authors: Jessica L Faulkner; Nicole L Plenty; Kedra Wallace; Lorena M Amaral; Mark W Cunningham; Sydney Murphy; Babbette LaMarca Journal: Prostaglandins Other Lipid Mediat Date: 2017-09-22 Impact factor: 3.072